Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone?

被引:1
作者
Buckman, Robert [1 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada
关键词
D O I
10.1016/j.breast.2011.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:483 / 484
页数:2
相关论文
共 4 条
  • [1] Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels[J]. Colleoni, M;Rocca, A;Sandri, MT;Zorzino, L;Masci, G;Nolè, F;Peruzzotti, G;Robertson, C;Orlando, L;Cinieri, S;de Braud, F;Viale, G;Goldhirsch, A. ANNALS OF ONCOLOGY, 2002(01)
  • [2] Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide[J]. Emmenegger, Urban;Francia, Giulio;Chow, Annabelle;Shaked, Yuval;Kouri, Andrew;Man, Shan;Kerbel, Robert S. NEOPLASIA, 2011(01)
  • [3] Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo[J]. Norrby, Klas;Nordenhem, Arvid. APMIS, 2010(12)
  • [4] SOON WN, 2010, J CLIN ONCOL, V28, P723